Olufunmilayo Ilori
Nurse Practitioner · Union, NJNPI 1700142445
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $107,736 of the $133,341 with a category attached, or 80.8%. Neurocrine Biosciences, Inc. accounts for 65.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2021 at $39,568 and has fallen 83.7% since, to $6,439 in 2025. Among nurse practitioner clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $335.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$87K
- Otsuka America Pharmaceutical, Inc.$27K
- AbbVie$16K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$904
- Teva Pharmaceuticals USA, Inc.$666
- Alkermes, Inc.$411
- plus $1K from 8 others
What the payments were for
- Consulting fees$6,5635%
- Speaking & faculty fees$107,73681%
- Grants$1,2001%
- Travel & lodging$7,6066%
- Food & beverage$10,0938%
- Education$1430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 90 | $86,959 |
| Otsuka America Pharmaceutical, Inc. | 93 | $27,305 |
| AbbVie | 102 | $16,087 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $904 |
| Teva Pharmaceuticals USA, Inc. | 23 | $666 |
| Alkermes, Inc. | 10 | $411 |
| E.r. Squibb & Sons, L.L.C. | 9 | $368 |
| Sunovion Pharmaceuticals Inc. | 16 | $232 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $115 |
| Axsome Therapeutics, Inc. | 1 | $109 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $99 |
| Bausch Health US, LLC | 3 | $47 |
| Lundbeck LLC | 2 | $25 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$86,085
- ABILIFY MAINTENA$26,345
- VRAYLAR$14,675
- ABILIFY ASIMTUFII$11,798
- CAPLYTA$355
- COBENFY$250
- VIVITROL$239
- AUSTEDO$125
- Austedo XR$122
- Auvelity$109
How this compares
$133,341 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 15 | $47,927 |
| VraylarCariprazine Hcl | 22 | $29,754 |
| CaplytaLumateperone Tosylate | 17 | $29,599 |
| Quetiapine Fumarate | 225 | $4,944 |
| Risperidone | 184 | $4,485 |
| Olanzapine | 122 | $3,435 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $2,735 |
| Divalproex Sodium ErDivalproex Sodium | 50 | $2,423 |
| Divalproex Sodium | 92 | $2,210 |
| Carbamazepine ErCarbamazepine | 20 | $2,208 |
| Bupropion XlBupropion Hcl | 49 | $1,602 |
| Duloxetine Hcl | 27 | $1,446 |
| Oxazepam | 11 | $1,437 |
| Sertraline Hcl | 87 | $1,428 |
| Fluoxetine Hcl | 64 | $1,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $16,087 | $29,75422 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $904 | $29,59917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.
Other nurse practitioner in Union
- Adewale AdefowojuUnion$70K
- Nancy BonnetMorristown$407K
- Vanessa CoppolaCloster$205K
- Janice BeitzHaddon Heights$75K
- Sophia KimEnglewood$70K
- Elizabeth FletcherCamden$62K
- Lannae EwingLinwood$39K
- Beth SavageNew Brunswick$34K
- Tina OcchiutoMorristown$25K
- Brandee FonsecaAudubon$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.